0
     

Report Added
Report already added
Non Alcoholic Fatty Liver Disease (NAFLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Non Alcoholic Fatty Liver Disease (NAFLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 31, 23, 3, 53 and 18 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Non Alcoholic Fatty Liver Disease (NAFLD) - Overview
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development
Non Alcoholic Fatty Liver Disease (NAFLD) - Drug Profiles
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects
Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products
Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones
Featured News & Press Releases
Jan 31, 2022: MediciNova receives a notice of allowance for a new patent covering MN-001 and MN-002 for hepatic ballooning in Canada
Jan 31, 2022: MediciNova receives a notice of allowance for a new patent covering MN-002 for hepatic ballooning in Canada
Jan 30, 2022: Madrigal Pharmaceuticals to announce topline results from the phase 3 MAESTRO-NAFLD-1 study of Resmetirom on Monday, January 31st
Jan 11, 2022: Galmed continues to drive innovation with three new US patents granted for aramchol and its meglumine salt
Dec 30, 2021: Madrigal provides update on timeline for topline results from the Phase 3 MAESTRO-NAFLD-1 clinical trial of Resmetirom
Nov 29, 2021: ENDRA Life Sciences expands pharmaceutical partnerships with VGI Health Technology to provide TAEUS for patient screening and biomarker measurement for phase 2 study
Nov 24, 2021: Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021
Nov 11, 2021: MediciNova announces MN-001 (tipelukast) data regarding lipid metabolism in NASH/NAFLD to be presented at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
Oct 28, 2021: Can-Fite’s NASH patents granted and allowed in Japan, Hong Kong, and Mexico
Oct 22, 2021: Synthetic doses subjects in Phase I trial of therapy for GI diseases
Oct 21, 2021: MediciNova announces abstract regarding the mechanism by which MN-001 (tipelukast) alters triglyceride metabolism accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021)
Oct 13, 2021: Gannex announces presentation on ASC43F at The Liver Meeting 2021 by American Association for the Study of Liver Diseases
Oct 13, 2021: Gannex announces presentation on ASC41 at The Liver Meeting 2021 by American Association for the Study of Liver Diseases
Sep 14, 2021: VGI Health Technology appoints Gallipoli Medical Research Foundation as NAFLD/NASH clinical study site
Sep 07, 2021: Xuanzhu Biopharm’s medical product XZP-6019 obtained approval for clinical trials of non-alcoholic fatty liver disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Companies, 2022 (Contd..3)
Number of Products under Development by Companies, 2022 (Contd..4)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Target, 2022 (Contd..2)
Number of Products by Stage and Target, 2022 (Contd..3)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
Number of Products by Stage and Mechanism of Action, 2022 (Contd..3)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by 89bio Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by ABIONYX Pharma SA, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Afimmune Biopharma Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Agentix Corp, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Albireo Pharma Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Alfasigma SpA, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Altimmune Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Amgen Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Amicogen Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AptamiR Therapeutics Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Ascletis Pharma Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Asdera LLC, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AtoGen Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by BAR Pharmaceuticals Srl, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bast Biotechnology LLC, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bausch Health Companies Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Beijing FuKangren Bio-pharm Tech Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bird Rock Bio Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bristol-Myers Squibb Co, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Carmot Therapeutics Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Chemomab Therapeutics Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by China NT Pharma Group Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by CohBar Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corvidane, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by CVI Pharmaceuticals US Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corp, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eli Lilly and Co, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Enspire Bio Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Esperion Therapeutics Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Evgen Pharma Plc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Fujian Cosunter Pharmaceutical Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Future Medicine Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by GemVax & KAEL Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gila Therapeutics Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by HCW Biologics Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Hepion Pharmaceuticals Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by HK inno.N Corp, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by HysensBio Corp, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Immuron Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Inmune Bio Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Inorbit Therapeutics AB, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Inventiva SA, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Ionis Pharmaceuticals Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by J2H Biotech, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kaleido Biosciences Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kinomedica Pty Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by KoBioLabs Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kowa Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Liminal BioSciences Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Lipidio Pharmaceuticals Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Macrophage Pharma Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Macrophage Therapeutics Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Madrigal Pharmaceuticals Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Metacrine Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Micelle BioPharma Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Mina Therapeutics Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Nano Intelligent Biomedical Engineering Corp, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NGM Biopharmaceuticals Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Nippon Chemiphar Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Nivarta Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Novartis AG, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NovMetaPharma Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NovoBiome SAS, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NuSirt Biopharma Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Oncocross Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by PegBio Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Petri Bio LLC, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Pfizer Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by PharmaKing Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Phenex Pharmaceuticals AG, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Poxel SA, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by PTC Therapeutics Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Renova Therapeutics Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sagimet Biosciences Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Salix Pharmaceuticals Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Scohia Pharma Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by SparkBioPharma Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sveikatal Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Synthetic Biologics Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by T3D Therapeutics Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TES Pharma SRL, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Theratechnologies Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Uni-Bio Science Group Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Verseon Corp, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by VGI Health Technology Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Vidasym Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Viking Therapeutics Inc, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zedira GmbH, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Lifesciences Ltd, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, 2022
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, 2022 (Contd..1)
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, 2022 (Contd..2)
Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Non Alcoholic Fatty Liver Disease (NAFLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline